Jaguar Health Announces New Patent Issued In Hong Kong For Napo Pharmaceuticals' Crofelemer In Treating Short Bowel Syndrome And Related Conditions
Jaguar Health Announces New Patent Issued In Hong Kong For Napo Pharmaceuticals' Crofelemer In Treating Short Bowel Syndrome And Related Conditions
jaguar health宣佈，在香港發行了一項新專利，授權Napo製藥公司使用Crofelemer治療短腸綜合症及相關疾病。
Jaguar Supports Proof-Of-Concept Studies For Rare Disease Indications With Results Expected By End Of 2024 And 2025
捷豹支持罕見病概念驗證研究，預計將在2024年和2025年末公佈結果
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。